The properties of
bucillamine, a synthetic
antioxidant, have been attributed mainly to the donation of
thiol groups to
glutathione (GSH). We recently demonstrated that
glutamate-cysteine ligase catalytic subunit (GCLC), the rate-limiting
enzyme of GSH biosynthesis, and the
multidrug-resistance-associated protein 2 (Mrp2/MRP2) are coordinately induced in response to
xenobiotic through the activation of the antioxidant-response element (ARE) by nuclear factor-erythroid 2 p45-related factor (Nrf2). We tested the hypothesis that
bucillamine and its oxidized metabolite
SA 981 also activate the Nrf2 pathway, thereby increasing
glutathione biosynthesis in human HepG2 and murine Hepa 1-6
hepatoma cell lines, through the induction of the GCLC
enzyme as well as the Mrp2/MRP2 transporter, which mediates the excretion of
glutathione and its conjugates from hepatocytes. Both
bucillamine and
SA 981 produced a significant dose-dependent increase in the
mRNA levels of Mrp2/MRP2 and GCLC after 24 h. The levels of the
transcription factor Nrf2 in the nuclei were maximal at 3 h, remained elevated at 6 h, and decreased to control values at 24 h in both cell lines. Moreover, both
bucillamine and
SA 981 significantly increased the expressions of Mrp2/MRP2 and GCLC
proteins in both cell lines. Finally, in both cell lines,
bucillamine and
SA 981 increased the GSH content two- to three-fold. These results demonstrate that
bucillamine and
SA 981 activate the ARE-ARE pathway increasing the expression of ARE-driven genes such as those of GCLC and Mrp2/MRP2. The role of
bucillamine as a chemopreventive agent against
cancer remains to be elucidated.